Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. \DE\LFCR · Entity 6447 | Director · Chief Executive Officer | May 20, 2026 | May 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LIFECORE BIOMEDICAL, INC. \DE\
Report date May 20, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 592,915 |
Reported balance
After 2026-05-20 transaction · row 1
1 source rowRow 1 · 2026-05-20 · Tax withholding · Disposed 40,413 · Balance 592,915 F1: Represents number of shares withheld by the issuer to satisfy applicable tax withholding obligations in connection with the vesting and settlement of an RSU vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents number of shares withheld by the issuer to satisfy applicable tax withholding obligations in connection with the vesting and settlement of an RSU vesting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 20, 2026 Filed May 21, 2026 20:28 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | Tax withholdingCommon Stock | 40,413 | $4.57 | $184,687.41 |
DisclosureSEC source: 0002022547-26-000003 · wk-form4_1779395291.xml · nonDerivative · entry 1 Josephs Paul · CIK 0002022547 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 592,915 F1 · shares: Represents number of shares withheld by the issuer to satisfy applicable tax withholding obligations in connection with the vesting and settlement of an RSU vesting. Read SEC document |
| July 08, 2025 Filed Jul 10, 2025 20:41 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | Exercise / conversionPerformance-Based Restricted Stock Units · Derivative | 150,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001005286-25-000078 · wk-form4_1752180022.xml · derivative · entry 3 Josephs Paul · CIK 0002022547 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,350,000 Underlying: Common Stock · 150,000 shares Expires 2029-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon the Issuer's common stock achieving certain stock prices. F2 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon the Issuer's common stock achieving certain stock prices. F2 · price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon the Issuer's common stock achieving certain stock prices. F2 · derivative.exercise_date: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon the Issuer's common stock achieving certain stock prices. Read SEC document |
| July 08, 2025 Filed Jul 10, 2025 20:41 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | Tax withholdingCommon Stock | 54,857 | $8.19 | $449,278.83 |
DisclosureSEC source: 0001005286-25-000078 · wk-form4_1752180022.xml · nonDerivative · entry 2 Josephs Paul · CIK 0002022547 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 633,328 F3 · shares: Represents number of shares withheld by the issuer to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the performance stock unit award as reported in Table I. Read SEC document |
| July 08, 2025 Filed Jul 10, 2025 20:41 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | Exercise / conversionCommon Stock | 150,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001005286-25-000078 · wk-form4_1752180022.xml · nonDerivative · entry 1 Josephs Paul · CIK 0002022547 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 688,185 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The performance-based restricted stock units vested based on the Issuer's achievement of a stock price milestone. F2 · price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon the Issuer's common stock achieving certain stock prices. Read SEC document |
| May 20, 2025 Filed May 22, 2025 17:43 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | Tax withholdingCommon Stock | 21,532 | $6.63 | $142,757.16 |
DisclosureSEC source: 0001005286-25-000074 · wk-form4_1747935780.xml · nonDerivative · entry 1 Josephs Paul · CIK 0002022547 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 538,185 F1 · shares: Represents the amount of shares delivered to satisfy applicable tax withholding obligations in connection with an RSU vesting. Read SEC document |
| January 08, 2025 Filed Jan 8, 2025 21:10 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | PurchaseCommon Stock | 17,000 | $5.74 | $97,580.00 |
DisclosureSEC source: 0001628280-25-000943 · wk-form4_1736370610.xml · nonDerivative · entry 1 Josephs Paul · CIK 0002022547 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 559,717 Read SEC document |
| December 06, 2024 Filed Dec 10, 2024 21:26 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | Tax withholdingCommon Stock | 11,769 | $7.15 | $84,148.35 |
DisclosureSEC source: 0001628280-24-050620 · wk-form4_1733866009.xml · nonDerivative · entry 2 Josephs Paul · CIK 0002022547 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 542,717 F1 · shares: Represents the amount of shares delivered to satisfy applicable tax withholding obligations in connection with the stock grant. Read SEC document |
| December 06, 2024 Filed Dec 10, 2024 21:26 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | GrantCommon Stock | 38,461 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-050620 · wk-form4_1733866009.xml · nonDerivative · entry 1 Josephs Paul · CIK 0002022547 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 554,486 Read SEC document |
| May 20, 2024 Filed May 22, 2024 21:48 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | GrantPerformance-Based Restricted Stock Units · Derivative | 1,500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-024782 · wk-form4_1716414520.xml · derivative · entry 3 Josephs Paul · CIK 0002022547 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500,000 shares Expires 2029-05-20 F2 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · shares: Represents the maximum number of performance-based restricted stock units that can vest based on the Issuer's achievement of certain stock price milestones. F4 · derivative.exercise_date: The performance-based restricted stock units vest, if it all, based on the Issuer's achievement of certain stock prices. F3 · derivative.underlying_shares: Represents the maximum number of performance-based restricted stock units that can vest based on the Issuer's achievement of certain stock price milestones. Read SEC document |
| May 20, 2024 Filed May 22, 2024 21:48 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | Tax withholdingCommon Stock | 8,975 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-024782 · wk-form4_1716414520.xml · nonDerivative · entry 2 Josephs Paul · CIK 0002022547 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 516,025 F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. Read SEC document |
| May 20, 2024 Filed May 22, 2024 21:48 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | GrantCommon Stock | 525,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-024782 · wk-form4_1716414520.xml · nonDerivative · entry 1 Josephs Paul · CIK 0002022547 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 525,000 F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.